Literature DB >> 9087669

Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism.

L S Holliday1, A D Dean, R H Lin, J E Greenwald, S L Gluck.   

Abstract

High concentrations of nitric oxide (NO) inhibit bone resorption by mature osteoclasts. We examined the effects of low NO concentrations on osteoclast formation in mouse bone marrow cultures. The NO releasers sodium nitroprusside (SNP) and S-nitroso-N-acetyl-DL-penicillamine inhibited the formation of multinucleated cells expressing tartrate-resistant acid phosphatase (a marker for osteoclasts) when administered during the last 3 days of 6-day cultures (differentiation stage) but not during the first 3 days (proliferation stage). SNP (1 microM) completely inhibited pit formation on dentine wafers when added to cultures during osteoclast formation, but 100 microM SNP was required to inhibit pitting by mature osteoclasts. Conversely, the NO synthase inhibitors aminoguanidine and nitro-L-arginine methyl ester both increased osteoclast formation. Inhibition of osteoclast formation by NO likely was guanosine 3',5'-cyclic monophosphate (cGMP) dependent, as SNP increased cGMP in marrow cultures, and 1 mM 8-bromo-cGMP or dibutyryl-cGMP reduced osteoclast formation when administered during the differentiation stage. The cGMP-specific type V phosphodiesterase inhibitor, zaprinast (M & B 22948) also inhibited osteoclast formation (half-maximal inhibitory constant, 100 microM) only when added during the differentiation stage. We conclude that the differentiation stage of osteoclast formation is inhibited by increases in cGMP levels elicited by NO.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087669     DOI: 10.1152/ajprenal.1997.272.3.F283

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

Review 1.  Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Authors:  Scott P Nichols; Wesley L Storm; Ahyeon Koh; Mark H Schoenfisch
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

2.  PDE1B2 regulates cGMP and a subset of the phenotypic characteristics acquired upon macrophage differentiation from a monocyte.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-03       Impact factor: 11.205

3.  iNOS-derived nitric oxide stimulates osteoclast activity and alveolar bone loss in ligature-induced periodontitis in rats.

Authors:  Bruno S Herrera; Rodrigo Martins-Porto; Aline Maia-Dantas; Paula Campi; Luis C Spolidorio; Soraia K P Costa; Thomas E Van Dyke; Robert Gyurko; Marcelo N Muscara
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

Review 4.  The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.

Authors:  J F Whitfield; P Morley; G E Willick
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

5.  Soluble guanylate cyclase as a novel treatment target for osteoporosis.

Authors:  Jisha Joshua; Gerburg K Schwaerzer; Hema Kalyanaraman; Esther Cory; Robert L Sah; Mofei Li; Florin Vaida; Gerry R Boss; Renate B Pilz
Journal:  Endocrinology       Date:  2014-09-04       Impact factor: 4.736

Review 6.  Cyclic nucleotides and phosphodiesterases in monocytic differentiation.

Authors:  Angie L Hertz; Joseph A Beavo
Journal:  Handb Exp Pharmacol       Date:  2011

Review 7.  Exosomes: novel regulators of bone remodelling and potential therapeutic agents for orthodontics.

Authors:  L S Holliday; K P McHugh; J Zuo; J I Aguirre; J K Neubert; W J Rody
Journal:  Orthod Craniofac Res       Date:  2017-06       Impact factor: 1.826

Review 8.  Are cardiovascular disease and osteoporosis directly linked?

Authors:  Crystal Whitney; Darren E R Warburton; Jiri Frohlich; Sammy Y Chan; Heather McKay; Karim Khan
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.

Authors:  Shu-Fen Liou; Jong-Hau Hsu; I-Ling Lin; Mei-Ling Ho; Pei-Chuan Hsu; Li-Wen Chen; Ing-Jun Chen; Jwu-Lai Yeh
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

10.  Pulsating fluid flow affects pre-osteoblast behavior and osteogenic differentiation through production of soluble factors.

Authors:  Jianfeng Jin; Hadi Seddiqi; Astrid D Bakker; Gang Wu; Johanna F M Verstappen; Mohammad Haroon; Joannes A M Korfage; Behrouz Zandieh-Doulabi; Arie Werner; Jenneke Klein-Nulend; Richard T Jaspers
Journal:  Physiol Rep       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.